摘要
乳腺癌术后内分泌治疗现已广泛应用于临床,如抗雌激素药物、芳香化酶抑制剂等类药物。他莫昔芬是常用的抗雌激素药物,长期服用可能引发子宫内膜癌、子宫内膜增生等并发症。新型抗雌激素药物托瑞米芬对子宫内膜的影响仍有待进一步研究,芳香化酶抑制剂与他莫昔芬相比,可以明显减少子宫内膜病变。B超对子宫内膜病变的监测有重大意义。全文对抗雌激素药物和芳香化酶抑制剂这两大类药物对子宫内膜的影响及子宫内膜病变的监测作一综述。
The endocrine therapy with antiestrogen agents and aromatase inhibitors is widely used for breast cancer patients. The therapeutic effect has also been confirmed in clinical applications.Tamoxifen is a kind of antiestrogen agent,which is frequently used in breast cancer. Long terms of using of tamoxifen will lead to serious consequence,such as uterine hyperplasia and endometrial cancer. As a new type of antiestrogen agent,the effect of toreminfene need to be further studied. Compared to tamoxifen,aromatase inhibitors can significantly decrease endometrial disease. Ultrasonography is of great value in monitoring of endometrium. This article summarizes the impact of antiestrogen and aromatase inhibitors on endometrium and the monitoring of endometrial disease in breast cancer patients receiving endocrine therapy.
作者
李羽禾
何玥
吴玉梅
LI Yu-he;HE Yue;WU Yu-mei(Beijing Obstetrics and Gynecology Hospital,Capital Medical University,Beijing 100006,China)
出处
《肿瘤学杂志》
CAS
2019年第3期261-263,共3页
Journal of Chinese Oncology
基金
首都卫生发展科研专项(首发2018-4-2113)
关键词
乳腺癌
内分泌治疗
子宫内膜病变
B超
breast cancer
endocrine therapy
endometrial disease
B ultrasound
